On June 14, Optigenix International, a joint venture between DB Capital Management, an American investment company, and Optigene-X, LLC, a company providing anti-aging nutraceuticals, announced it was expanding the joint venture to include CampaMed LLC, an American company providing nutraceutical products. The CampaMed product line was formulated by Dr. Ronald Pero, chairman of CampaMed, and a world-recognised expert in the field of DNA research. The company formed by the joint venture will be granted an exclusive license to distribute CampaMed's unique and patented product line, and will target the US$26bn nutritional supplement market. Unlike most products in this market, the nutraceuticals distributed by the new company consist of proprietary nutritional formulas designed by respected physicians and genetic scientists, and are backed by years of rigorous scientific research and clinical studies. According to John C. Flanders, Jr., CEO of Digital Bridge, the participation of CampaMed will provide the joint venture with a wider line of nutraceuticals, which will leverage their distribution channels. He claims it will assist them in dominating this market. CampaMed and Optigene-X will each grant an exclusive, worldwide, and perpetual license to the Joint Venture to distribute their respective products. Source: Business Wire
